Evidence map›Paper›PMID 36649711›Full record

ArticleCell reports2023

Protein folding stress potentiates NLRP1 and CARD8 inflammasome activation.

Elizabeth L Orth-He, Hsin-Che Huang, Sahana D Rao, Qinghui Wang, Qifeng Chen, Claire M O'Mara, Ashley J Chui, Michelle Saoi, Andrew R Griswold, Abir Bhattacharjee and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Mechanistic insights from inflammasome structures.Nature reviews. Immunology · 2024
    Review
  15. Review
  16. Article
  17. Translational cancer research · 2024
    Article
  18. NLRP inflammasomes in health and disease.Molecular biomedicine · 2024
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Elizabeth L Orth-HeTri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Hsin-Che HuangTri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sahana D RaoTri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Qinghui WangChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Qifeng ChenChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Claire M O'MaraChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ashley J ChuiTri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Michelle SaoiDonald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Andrew R GriswoldWeill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY 10065, USA; Pharmacology Program of the Weill Cornell Graduate School of Medical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Abir BhattacharjeeChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Daniel P BallChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Justin R CrossDonald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Daniel A BachovchinTri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY 10065, USA; Pharmacology Program of the Weill Cornell Graduate School of Medical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: bachovcd@mskcc.org.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1M
Characterizing the Mechanism of DPP8/9 Inhibitor-Induced PyroptosisR01AI137168 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Bachovchin · 2018 to 2026
$4.3M
Prolidase Inhibitors as Therapeutic Agents for Acute Myeloid LeukemiaR01CA266478 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Bachovchin · 2022 to 2026
$3.1M
Redox control of the NLRP1 inflammasomeR01AI163170 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI BACHOVCHIN, DANIEL · 2021 to 2025
$2.6M
Tri-Institutional PhD Program in Chemical BiologyT32GM115327 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI TAN, DEREK S · 2015 to 2019
$741k
Characterizing the DPP8/9 Pyroptotic Checkpoint with Chemoproteomic Protease Substrate ProfilingF30CA243444 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GRISWOLD, ANDREW · 2019 to 2022
$193k
NCI NIH HHS F30 CA243444NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA266478NIAID NIH HHS R01 AI137168NIAID NIH HHS R01 AI163170NIGMS NIH HHS T32 GM007739NIGMS NIH HHS T32 GM115327
6 · The paper itself

Abstract

NLRP1 and CARD8 are related pattern-recognition receptors (PRRs) that detect intracellular danger signals and form inflammasomes. Both undergo autoproteolysis, generating N-terminal (NT) and C-terminal (CT) fragments. The proteasome-mediated degradation of the NT releases the CT from autoinhibition, but the stimuli that trigger NT degradation have not been fully elucidated. Here, we show that several distinct agents that interfere with protein folding, including aminopeptidase inhibitors, chaperone inhibitors, and inducers of the unfolded protein response, accelerate NT degradation. However, these agents alone do not trigger inflammasome formation because the released CT fragments are physically sequestered by the serine dipeptidase DPP9. We show that DPP9-binding ligands must also be present to disrupt these complexes and allow the CT fragments to oligomerize into inflammasomes. Overall, these results indicate that NLRP1 and CARD8 detect a specific perturbation that induces both protein folding stress and DPP9 ligand accumulation.

Indexed as

Adaptor Proteins, Signal TransducingInflammasomesApoptosis Regulatory ProteinsCARD Signaling Adaptor ProteinsNLR ProteinsProtein FoldingAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsCARD Signaling Adaptor ProteinsInflammasomesNLR ProteinsaminopeptidasesCARD8CP: ImmunologyDPP8/9inflammasomesNLRP1peptidesprotein folding

Identifiers

PMID36649711
PMCPMC10042216
OpenAlexW4316495420

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.